DOTMATICS
30.3.2017 09:02:08 CEST | Business Wire | Press release
Dotmatics , a leading provider of scientific informatics solutions and services, today announced Reaction Workflows (RW), a major new application within the Dotmatics 5.1 suite that lets scientists quickly and easily define and execute common cheminformatics tasks, such as library enumeration, structure normalization and compound profiling, in a graphical workflow environment.
RW, part of the integrated Dotmatics 5.1 informatics suite, allows scientists to produce an easily understandable graphical record for sharing scientific best practices and knowledge retention within an organization. Scientists can develop workflows quickly and easily using an intuitive, drag-and-drop web-based interface without programming or scripting experience.
“Reaction Workflows provides the ability for any chemist within a company to easily perform an important set of cheminformatics tasks,” said Dotmatics’ Director and Chief Scientific Officer Mike Hartshorn, Ph.D. “This application complements the enhanced user experience and increased accessibility in our 5.1 platform suite by allowing scientists to perform their own ad-hoc analysis without the need for additional resources. This removes a common and time-consuming roadblock to meeting their goals.”
Intuitive User Interface
Within RW, workflows are built from nodes that provide inputs and outputs or perform actions. Using the drag-and-drop interface, the nodes are joined together to define a data process to perform. This makes designing or modifying workflows significantly faster and less prone to error than manual development without requiring specialized technical skills.
Immediate Productivity
The application includes a variety of chemically intelligent nodes including ones to perform reaction-, scaffold-, and transform-based enumeration. Nodes for performing structure normalization, property calculation, substructure annotation and filtering are also available. Other nodes read and write chemical structures and visualize the results or send them to Dotmatics Vortex for further analysis. The ability to perform the different types of enumeration in combination with property/structure annotation and filtering means it can be used for many common medicinal chemistry use cases. Nodes come populated with external content to ensure that chemists can be immediately productive. For example:
- The reaction node provides an extensive list of pre-built chemical reactions that are commonly used in synthetic and medicinal chemistry.
- The transform node provides a set of structural changes that are performed in medicinal chemistry to alter structures. Further reactions, transforms or scaffolds can be added easily.
- The reagent node is preconfigured with common sets of chemical reagents from Dotmatics Chemselector .
Chemistry teams or individuals can add and share additional reactions and other content to these stores based on proprietary corporate knowledge.
Address Wide Variety of Tasks
Reaction Workflows is a highly flexible application where multiple cheminformatics nodes can be joined together to build workflows quickly and thoroughly. Typical use cases include reaction-based enumeration, Markush-based enumeration, virtual library-enumeration, and profiling and structure normalization for registration. The application also allows scientists to create workflows for lead hopping, filtering and profiling sets of structures by properties and substructures. It even allows for the creation of workflows that address the important but mundane task of chemistry file cleanup, which allows cheminformaticians to automate the correction of errors and inconsistencies in data and structure files, prior to their use in design.
Integrates with Dotmatics Applications
RW is integrated into the Dotmatics Suite. Browser hit lists, for example, sets of reagents, can be used as input into the reagents node. A Vortex node can be inserted into a workflow so that the results of an enumeration and an interactive selection in Vortex can provide input to the next node in the workflow.
An Introducing Dotmatics Reaction Workflows webinar will be held Thursday, April 6, 2017, from 10:30-11:30 am Eastern Time. A What’s New in Dotmatics 5. 1 webinar will be held May 9, 2017, from 10:30-11:30 am Eastern Time. Dotmatics presenters Phil Mounteney, head of application science, North America and Gianpaolo Bravi, senior scientist and one of the lead developers of RW, will provide a product overview and lead a demonstration. To register for the April 6 webinar click here . To register for the May 9 webinar click here . A video of 5.1 including Reaction Workflows is available here .
About Dotmatics:
Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and supported on Microsoft Windows, Mac OS X and Linux. For more information visit dotmatics.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005447/en/
Contact:
Dotmatics
Marla Kertzman, +1 209-852-9027
pr@dotmatics.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
